FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and is a humanized antibody, which, using IGF-I receptor, increases muscle mass, but do not reduce a blood glucose level. This humanized antibody is a humanized antibody against a human IGF-I receptor, its fragment, or its derivative, and it has a specific amino acid sequence. The invention concerns the use of the antibody as part of pharmaceutical compositions for the treatment of diseases, such as muscular atrophy or dwarfism.
EFFECT: obtainment of a humanized antibody against IGF-I receptor.
18 cl, 4 dwg, 10 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANIZED IGF-1 RECEPTOR ANTIBODY | 2021 |
|
RU2836869C1 |
| COMPOSITION FOR TREATING IGF-1R EXPRESSING CANCER | 2016 |
|
RU2728568C2 |
| VARIANTS OF FC-REGION WITH MODIFIED ABILITY TO BIND TO FCRN AND WITH PRESERVED ABILITY TO BIND WITH PROTEIN A | 2015 |
|
RU2727639C2 |
| VERSIONS OF THE FC-DOMAIN WITH MODIFIED ABILITIES TO BIND TO FCRN | 2015 |
|
RU2730592C2 |
| VERSIONS OF Fc-REGION WITH ALTERED BINDING TO NEONATAL Fc-RECEPTOR (FcRn) FOR USE IN VETERINARY SCIENCE | 2019 |
|
RU2830231C2 |
| METHODS OF PREVENTING AND TREATING HEART DISEASES | 2018 |
|
RU2830232C2 |
| MODIFIED CONSTANT REGION OF ANTIBODY | 2023 |
|
RU2837820C2 |
| CANINE ALPHA INTERLEUKIN-4 RECEPTOR ANTIBODIES | 2020 |
|
RU2840044C1 |
| TUMOR-TARGETING AGONIST CD28 ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2837821C1 |
| MODIFIED ANTIBODY CONSTANT REGION | 2021 |
|
RU2797273C2 |
